- Home
- RIGL vs BBN Comparison
RIGL vs BBN Comparison
Compare RIGL & BBN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RIGL | BBN |
|---|---|---|
| Founded | 1996 | 1983 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance Companies |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 911.8M | 899.7M |
| IPO Year | 2000 | 2010 |
Fundamental Metrics
Financial Performance| Metric | RIGL | BBN |
|---|---|---|
| Price | $51.03 | $14.87 |
| Analyst Decision | Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $63.00 | N/A |
| AVG Volume (30 Days) | 187.5K | ★ 351.9K |
| Earning Date | 11-05-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 6.90% |
| EPS Growth | ★ 1867.68 | N/A |
| EPS | ★ 1.32 | N/A |
| Revenue | ★ $294,282,000.00 | N/A |
| Revenue This Year | $3.89 | N/A |
| Revenue Next Year | $21.95 | N/A |
| P/E Ratio | $38.83 | ★ N/A |
| Revenue Growth | ★ 64.15 | N/A |
| 52 Week Low | $24.84 | $14.16 |
| 52 Week High | $52.24 | $17.45 |
Technical Indicators
Market Signals| Indicator | RIGL | BBN |
|---|---|---|
| Relative Strength Index (RSI) | 61.97 | 58.46 |
| Support Level | $44.83 | $14.16 |
| Resistance Level | N/A | $16.02 |
| Average True Range (ATR) | 1.53 | 0.16 |
| MACD | 0.30 | 0.07 |
| Stochastic Oscillator | 75.79 | 95.16 |
Price Performance
Historical ComparisonAbout RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, REZLIDHIA (olutasidenib), GAVRETO (pralsetinib), R289, and Ocadusertib (Systemic) - Eli Lilly.
About BBN BlackRock Taxable Municipal Bond Trust of Beneficial Interest
BlackRock Taxable Municipal Bond Trust is a diversified, closed-end management investment company. Its investment objective is to seek high current income, with a secondary objective of capital appreciation. The Trust seeks to achieve its investment objectives by investing in a portfolio of taxable municipal securities, including Build America Bonds (BABs), issued by state and local governments to finance capital projects such as public schools, roads, transportation infrastructure, bridges, ports and public buildings.